Semaglutide 3mg tablets: what this dose is, and what it isn't

What exactly is a semaglutide 3mg tablet, and who is it prescribed for?

Rybelsus (the branded name for oral semaglutide in 3mg, 7mg and 14mg doses) is prescribed to adults with type 2 diabetes to help control blood glucose levels. The 3mg dose is a starter dose for Rybelsus, used during the first month of treatment to let the body adjust before the prescriber moves a patient up to 7mg or 14mg. It has no licensed role in weight management. The oral semaglutide landscape in the UK now includes both a diabetes formulation and a weight-loss formulation, and the two should not be confused simply because they share an active ingredient.

The MHRA licenses medicines for specific indications, and a prescriber who issues Rybelsus for weight loss rather than diabetes would be doing so off-label, which is legally permitted in some clinical contexts but requires a clear, documented rationale. For routine private weight-loss treatment through a regulated online pharmacy, the relevant medicine is the MHRA-approved weight-loss version. You can read more about how the oral semaglutide weight-loss tablet differs from Rybelsus in detail.

So what dose schedule do the weight-loss semaglutide tablets actually follow?

Wegovy tablets use doses that do not overlap with Rybelsus at all. Treatment starts at 1.5mg once daily, moves to 4mg after at least a month, then 9mg, and finally reaches a 25mg maintenance dose, the strongest licensed step. Each stage requires at least one month before escalation, and a prescriber reviews the plan throughout. The 3mg and 7mg levels simply do not appear in this schedule; they belong to the Rybelsus diabetes titration, which is why searching for semaglutide 7mg tablets can create similar confusion.

Wegovy tablets must be taken first thing in the morning on an empty stomach with a small amount of plain water (up to around 120ml), and you should wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. Unlike the injectable Wegovy pen, the tablets need no refrigeration, which makes them straightforwardly travel-friendly. That practicality is part of what made the June 2026 approval significant, the MHRA's recent semaglutide approvals reflect how quickly the evidence base for this drug class is moving.

Does switching between Rybelsus and the weight-loss tablet require starting from scratch?

This is a question our prescribers hear regularly. If a patient is already established on the 2.4mg weekly injectable dose of Wegovy, they may be able to move directly to the 25mg oral tablet rather than re-titrating from 1.5mg, but that transition is a clinical decision, not a patient-led one. Anyone moving between formulations needs an assessment that accounts for their current dose, how well they have tolerated treatment, and whether the change is clinically appropriate for them personally.

People who have been prescribed Rybelsus for type 2 diabetes and are also looking to manage their weight sit in a more complex clinical picture. Both conditions may be addressed by a semaglutide-based medicine, but not necessarily the same one at the same time. A prescriber must map out that plan. It is worth noting, too, that Wegovy tablets are not currently available on the NHS, a NICE appraisal would be required before NHS commissioning could begin, so access today is through the private prescription route. If you are weighing up the options, the cost of Wegovy tablets privately is a practical factor worth understanding before you start.

What should you do if you've been offered semaglutide 3mg tablets for weight loss online?

Be cautious. Legitimate UK pharmacies dispense prescription-only medicines only after clinical assessment by a qualified prescriber; they do not supply Rybelsus for weight management as a routine offering, and any website selling semaglutide tablets without a prescription should be treated as a serious red flag. The MHRA has issued repeated warnings about illegally traded weight-loss medicines online, and suspect sellers can be reported through the Yellow Card scheme.

If you want to explore whether oral semaglutide for weight loss is appropriate for you, the right starting point is a structured clinical consultation, not a search result offering a specific dose. You can read about Wegovy tablets in full to understand what the approval covers, or look at what the trial evidence actually shows before deciding whether to take things further. For a broader view of evidence-based weight-loss options, the weight-loss treatments overview is a good place to start. Our clinical team (led by a GPhC-registered Independent Prescriber) reviews every consultation personally. Speak to our prescribers if you'd like to find out whether treatment is right for you.